Adam Shlien

Featured in: Favicon

nature.com Favicon

biomedcentral.com Favicon

jamanetwork.com Favicon

aacrjournals.org Favicon

ascopubs.org Favicon

genomebiology.biomedcentral.com Favicon

cancerres.aacrjournals.org

Articles

Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns - Nature Communications

Aug 26, 2024 | nature.com | Ping Luo |Nicholas Fischer |Vallijah Subasri |Adam Shlien |Raymond Kim |David Malkin | +2 more

AbstractGermline pathogenic TP53 variants predispose individuals to a high lifetime risk of developing multiple cancers and are the hallmark feature of Li-Fraumeni syndrome (LFS). Our group has previously shown that LFS patients harbor shorter plasma cell-free DNA fragmentation; independent of cancer status.
Spontaneous expression of the CIC::DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma formation in genetically engineered mice - Oncogene

Feb 26, 2024 | nature.com | Adam Shlien

AbstractCIC::DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no effective treatments and efforts to identify and translate better therapies are limited by the scarcity of patient tumor samples and cell lines. To address this limitation, we generated three genetically engineered mouse models of CDS (Ch7CDS, Ai9CDS, and TOPCDS).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →